Figure 2.
Overall survival curves in 182 patients with PMF, stratified by the presence of adverse (ASXL1, SRSF2, CBL, KIT, RUNX1, SH2B3, and CEBPA) vs nonadverse variants/mutations vs no DNA sequence variants/mutations.
Overall survival curves in 182 patients with PMF, stratified by the presence of adverse (ASXL1, SRSF2, CBL, KIT, RUNX1, SH2B3, and CEBPA) vs nonadverse variants/mutations vs no DNA sequence variants/mutations.
